Takeda, University of Kyoto Partner on CNS Drug Targets and Biomarkers

The five-year deal is focused on developing new drugs for obesity and schizophrenia.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.